Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
Terminated · Phase 3 · NCT05695391
Conditions: Hemophilia
At a glance
- Research payments reported, 2025
- $130,843
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 2
About the trial
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Tested
- Coagulation Factor VIIa (Recombinant) (biological)
- Dates
- Started 2024-06-07; completion 2025-07-07
- Results posted
- Yes
This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII) or factor IX (FIX) undergoing elective major surgical procedures.
From ClinicalTrials.gov, last updated 2026-07-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Hema Biologics, LLC reported $130,843 in research payments for this study in 2025 (23 payments).
Products named: Sevenfact
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $120,643
- University of Texas Health Science Center at Houston (ut Health) $10,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.